AMSTERDAM & LEXINGTON, Mass.--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) today announced data, presented during the 20th United European Gastroenterology Week (UEGW), which adds to the growing body of clinical and preclinical evidence of the influence EndoBarrier® Therapy may have on key intestinal hormones that control appetite and glucose metabolism. GI Dynamics and several of its collaborators have now shown in animal models and clinical studies that much like gastric bypass surgery, EndoBarrier Therapy affects critical metabolic hormones, including the gut peptides glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP) and peptide YY (PYY), as well as insulin, glucagon, ghrelin and leptin.
